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There is an urgent need for the development of treatments and preventative 
therapies for opioid use disorder. Approximately 27 million people worldwide suffer from an 
opioid use disorder, with the majority of people misusing heroin (1). In 2015, it was globally 
estimated that 118,000 deaths were attributed directly to opioid use, and overdoses 
accounted for up to half of these deaths (1). Beyond the risk of overdosing, unsafe drug 
injection techniques pose another threat to opioid users – the spread of virally-transmitted 
diseases. This commentary, which will highlight the work of Venniro et al. published in this 
issue of Biological Psychiatry (2), argues that a multi-model research approach should be 
used to enhance our understanding of addiction and develop therapies. 
Across individuals, a combination of factors contributes to the development and 
escalation of drug use. Accordingly, personalized delivery of both biomedical and 
psychosocial treatments may have the most significant impact for the individual who is either 
trying to achieve abstinence or lessen potential addiction-related harms. Biomedical 
interventions for opioid use disorder may involve transferring the individual onto another, 
safer drug. Methadone and buprenorphine, for example, are sometimes used as substitution 
treatments for heroin addiction. While these replacement drugs might not bring about the 
same magnitude of desired effects as heroin, their use mitigates withdrawal symptoms. 
Furthermore, oral administration of these replacement drugs is safer than the injection of 
heroin.  
Psychosocial treatments for opioid use disorder can take many forms, ranging from 
forced court-ordered programs to voluntary cognitive and behavioral therapies. For example, 
in the United States, Hawaii’s Opportunity Probation with Enforcement program puts drug-
possession arrestees on probation and subjects them to random or scheduled drug tests. 
Failure to pass these tests results in short and predictable periods of incarceration, and this 
threat is believed to motivate abstinence. In contrast to strategies that combat addiction that 
involve punishment, contingency management therapies offer incentives or rewards (e.g., 
vouchers) to substance misusers for meeting specific behavioral goals (3). Similarly, 
community reinforcement programs provide a social reward (e.g., access to work, friends, 
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family) that is contingent upon stopping drug-use (4). Despite the achievements of these 
reward-based programs, they are expensive to run, abstinence success rates often diminish 
over time, and the danger of relapsing into drug misuse remains when the program ends (3, 
5). Regardless, the initial recovery observed during psychosocial programs highlights how 
individuals with a substance use disorder might be able to adapt their behavior to reduce 
drug-seeking and -taking. Furthermore, by combining biomedical and psychosocial 
therapies, long-term abstinence may be achievable.  
The magnitude of the opioid use crisis necessitates the development of preventative 
measures and new treatment options for the addiction. Much of our knowledge on how drug 
use impacts the brain is based on the study of preclinical animal models. In such 
experiments, the neurobiology of addiction is assessed in rodents (e.g., rats) that are placed 
in chambers and trained to perform an action (e.g., press a lever) to take a drug of abuse 
(e.g., heroin or cocaine). Unfortunately, scientific attempts to translate knowledge gained 
from these rodent studies to improve the human condition have been limited in their 
success. Perhaps one reason for this problem is that self-administration studies in rodents 
often do not consider psychosocial factors influencing addiction; it is essential to account for 
psychosocial features in animal models because such factors aid recovery in humans (3, 4).  
Translational medical research uses the knowledge gained from basic and preclinical 
studies to develop new therapies to treat disorders in people (a ‘bench to bedside’ 
approach). Reverse-translational research starts in the opposite direction: knowledge of how 
to effectively treat medical conditions in people (based on observation, experimentation, 
clinician expertise) informs the development of basic and preclinical research projects 
(Figure 1). Objectives of reverse-translational research include understanding why 
treatments work and refining/improving therapies. Reverse-translational preclinical studies 
can account for psychosocial influences on addiction development and its treatment, 
including how giving substance misusers non-drug rewards can reduce their drug-intake (3, 
4). An example of such an approach is the rat community reinforcement model developed by 
Venniro and colleagues (2, 6). In this model, rats are first trained on separate operant tasks; 
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in distinct sessions, rats learn that by pressing one lever they receive an infusion of a drug 
reward (e.g., heroin), while pressing a different lever gives them a social reward (e.g., 
interaction with a familiar rat they have previously lived with). Later, when given a choice to 
press a lever for heroin or access to their social partner, rats primarily choose their partner 
over drug – the authors refer to this as ‘voluntary abstinence’ from the drug (2). Similar 
findings were also recently observed for methamphetamine (6).  
Another issue that Venniro et al. investigate is susceptibility to relapse into drug-
pursuit after re-exposure to cues (conditioned stimuli) that are predictive of drug availability. 
Studying how cues can instigate relapse is essential because neurological responsiveness 
to stimuli may predict relapse susceptibility in people (7). In this issue of Biological 
Psychiatry, Venniro et al. found that, compared to rats that underwent ‘forced abstinence’ 
from heroin (similar to going ‘cold turkey’), rats that had undergone ‘voluntary abstinence’ 
were less likely to ‘relapse’ into heroin pursuit (2). The ability of social reward choice to 
decrease ‘relapse’ was independent of sex. Similarly, the success of contingency 
management-based therapies appears to not differ by sex (9; other reports, however, 
suggest differences in patterns of drug-use between sexes in animal models and 
observations of human behavior - more research is needed). Finally, compared to previous 
articles, ‘voluntary abstinence’ was more successful at reducing ‘relapse’ into 
methamphetamine pursuit than ‘relapse’ for heroin (2, 6); this finding highlights the need for 
modeling and developing diverse treatment options across substance use disorders.   
In addition to successfully testing a reverse-translational animal model of addiction, 
Venniro and colleagues should be commended for publishing details on an improvement to 
their model (2). By doing so, they will enable other researchers to replicate and build upon 
their findings – hopefully, this can speed the collaborative development of treatments for 
addiction. The original version of the rat community reinforcement model required the 
experimenter to physically separate the rodent social partners in the operant chambers 
between trials during a single testing session (Experiment 1). Experiment 2 of their article 
removed the need for researcher intervention; an automated sliding door with a barrier was 
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installed in the operant chambers that enabled the rats to physically interact for a time-
limited period (2). The results from Experiment 2 mirrored those of Experiment 1, 
demonstrating how rats choose to be social instead of taking heroin, and that ‘voluntary 
abstinence’ may protect against ‘relapse’.  
Beyond reverse-translating the success of community reinforcement, other recent 
preclinical studies have developed representative models of addiction that are based on 
observations of human behavior. For example, evidence shows that people prefer to 
consume cocaine outside the home, while they prefer to take heroin at home – such findings 
are also seen in rats (9). Therefore, environmental contexts play pivotal roles in determining 
drug-choice. Could behavioral therapies perhaps be modeled in rats that alter motivation to 
consume a certain drug in specific settings?  
In another study, we created a preclinical model based on how certain people with a 
substance use disorder show flexibility and ingenuity when procuring drugs (10). We have 
argued that such observations of adaptable human behavior suggest that the act of drug-
seeking is not necessarily controlled by ‘drug-seeking habits’. Accordingly, we found that, 
despite the need to be flexible in their drug-seeking, rats still developed ‘addictive’ behaviors. 
Finally, recent preclinical models of addiction replicate the intermittent binge-like pattern by 
which people take cocaine (10). We and others have shown that rats who intermittently 
‘binge’ on a drug display exaggerated addiction-like behaviors compared to other animals 
that have continuous access to the drug. By accurately replicating in rodents how people 
seek and take drugs, basic research scientists may be better able to develop treatments for 
addiction.   
Addiction is an extremely complex condition that is influenced by numerous 
biopsychosocial factors, drugs of choice, and patterns of use. For example, Venniro et al. 
demonstrate drug-specific intricacies by showing how social choice prevents 
methamphetamine craving but only reduces heroin craving (2, 6). Additionally, if a drug is 
easily accessible to an individual (e.g., for a drug dealer with constant supply), then 
adaptability during drug-procurement may not be essential and, therefore, drug-seeking may 
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(to some extent) become controlled by habit. Thus, when trying to develop viable treatment 
options for addiction, it is critical to acknowledge how unlikely it is for any single preclinical 
model to capture the complete multi-faceted nature of substance use and misuse across 
drugs and people. Instead, scientists should accept that a variety of preclinical models of 
addiction are required to replicate the diverse contributing factors and features of addiction in 
people. By collaborating (instead of competing) on the design of translational and reverse-
translational preclinical models of addiction, we stand a better chance of creating accurate 
representations of the human condition that can be used to develop treatments for 
substance use disorders.        
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Figure 1. Reverse-translational strategy for developing substance use disorder treatments. 
General overview of how both how human observational and experimental studies can 
inform the design of preclinical models of addiction.  
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